An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine

INTRODUCTION: With the approval of the adjuvanted recombinant zoster vaccine (RZV; Shingrix, GSK) in October 2017, GSK established enhanced safety surveillance measures to allow prompt identification of potential safety signals not observed during clinical development. In Germany, cases of vesicular...

Descripción completa

Detalles Bibliográficos
Autores principales: Pirrotta, Paola, Tavares-Da-Silva, Fernanda, Co, Maribel, Lecrenier, Nicolas, Hervé, Caroline, Stegmann, Jens-Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8626369/
https://www.ncbi.nlm.nih.gov/pubmed/34622421
http://dx.doi.org/10.1007/s40264-021-01118-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8626369/
https://www.ncbi.nlm.nih.gov/pubmed/34622421
http://dx.doi.org/10.1007/s40264-021-01118-3

Ejemplares similares